Anti-tumour necrosis factor therapy is associated with certain subtypes of chronic rhinosinusitis

被引:6
作者
Leonard, C. G. [1 ]
Masih, C. [2 ]
McDonald, S. [2 ]
Taylor, G. [1 ]
Maiden, N. [2 ]
Leyden, P. J. [1 ]
机构
[1] Craigavon Area Hosp, Dept Otorhinolaryngol, Level 3 Secretarys Off, Craigavon, North Ireland
[2] Craigavon Area Hosp, Dept Rheumatol, Craigavon, North Ireland
关键词
Rhinitis; Allergic; Nonseasonal; Paranasal Sinus Disease; Paranasal Sinuses; Rheumatoid Arthritis; Ankylosing Spondylitis; GUIDELINES;
D O I
10.1017/S0022215116001067
中图分类号
R76 [耳鼻咽喉科学];
学科分类号
100213 ;
摘要
Background: Chronic rhinosinusitis has many risk factors; however, the effect of anti-tumour necrosis factor therapy has not been investigated in depth. Our experience points to a detrimental clinical effect in overall prevalence of chronic rhinosinusitis, despite its benefit in certain subtypes. Method: A telephone survey was performed to parallel the findings of the Global Allergy and Asthma European Network chronic rhinosinusitis screening survey. This was itself based on the widely recognised European Position Paper on Rhinosinusitis and Nasal Polyps criteria. Results: A total of 120 patients responded to the survey. The prevalence of chronic rhinosinusitis in the antitumour necrosis factor therapy population was 20 per cent (95 per cent confidence interval = 12.84-27.16). When compared using a chi-square test, for a two-by-two contingency table, this finding was significant against the prevalence recorded in the normal population. Conclusion: This is the first observational study indicating increased prevalence of chronic rhinosinusitis in patients treated with anti-tumour necrosis factor therapy. These clinical findings require investigation in greater depth to clarify the nature of pathologies currently diagnosed and treated as chronic rhinosinusitis.
引用
收藏
页码:560 / 564
页数:5
相关论文
共 50 条
  • [41] The Future Role of Anti-Tumour Necrosis Factor (TNF) Products in the Treatment of Rheumatoid Arthritis
    Giovanni Camussi
    Enrico Lupia
    Drugs, 1998, 55 : 613 - 620
  • [42] Accumulation of plasma nucleosomes upon treatment with anti-tumour necrosis factor-α antibodies
    D'Auria, F
    Rovere-Querini, P
    Giazzon, M
    Ajello, P
    Baldissera, E
    Manfredi, AA
    Sabbadini, MG
    JOURNAL OF INTERNAL MEDICINE, 2004, 255 (03) : 409 - 418
  • [43] Anti-tumour necrosis factor agent and liver injury: literature review, recommendations for management
    Rossi, Roberta Elisa
    Parisi, Ioanna
    Despott, Edward John
    Burroughs, Andrew Kenneth
    O'Beirne, James
    Conte, Dario
    Hamilton, Mark Ian
    Murray, Charles Daniel
    WORLD JOURNAL OF GASTROENTEROLOGY, 2014, 20 (46) : 17352 - 17359
  • [44] Influences of anti-tumour necrosis factor agents on postoperative recovery in patients with rheumatoid arthritis
    Hirano, Yuji
    Kojima, Toshihisa
    Kanayama, Yasuhide
    Shioura, Tomone
    Hayashi, Masatoshi
    Kida, Daihei
    Kaneko, Atsushi
    Eto, Yoshito
    Ishiguro, Naoki
    CLINICAL RHEUMATOLOGY, 2010, 29 (05) : 495 - 500
  • [45] Unregulated prescribing of anti-tumour necrosis factor agents does not mean inappropriate prescribing
    Ng, C. T.
    Radovits, B. J.
    Kievit, W.
    Fransen, J.
    van Riel, P. L. C. M.
    FitzGerald, O.
    Veale, D. J.
    Bresnihan, B.
    ANNALS OF THE RHEUMATIC DISEASES, 2010, 69 (01) : 313 - 314
  • [46] Microarray analysis for molecular characterization of disease activity and measuring outcomes of anti-tumour necrosis factor therapy in rheumatoid arthritis
    B Stuhlmüller
    T Häupl
    N Tandon
    M Hernandez
    C Hultschig
    RJ Kuban
    J Salfeld
    GR Burmester
    Arthritis Research & Therapy, 7
  • [47] Anti-tumour necrosis factor alpha therapy and increased risk of de novo psoriasis: is it really a paradoxical side effect?
    Joyau, C.
    Veyrac, G.
    Dixneuf, V.
    Jolliet, P.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2012, 30 (05) : 700 - 706
  • [48] Systematic review with meta-analysis: malignancies with anti-tumour necrosis factor-α therapy in inflammatory bowel disease
    Williams, C. J. M.
    Peyrin-Biroulet, L.
    Ford, A. C.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2014, 39 (05) : 447 - 458
  • [49] Microarray analysis for molecular characterization of disease activity and measuring outcomes of anti-tumour necrosis factor therapy in rheumatoid arthritis
    Stuhlmueller, B.
    Haeupl, T.
    Tandon, N.
    Hernandez, M.
    Hultschig, C.
    Kuban, R. J.
    Salfeld, J.
    Burmester, G. R.
    ARTHRITIS RESEARCH & THERAPY, 2005, 7 (Suppl 1) : S57 - S57
  • [50] The impact of anti-tumour necrosis factor therapy for rheumatoid arthritis on the use of other drugs and hospital resources in a pragmatic setting
    Sandhu, R. S.
    Treharne, G. J.
    Douglas, K. M. J.
    Cassim, K.
    Saratzis, A.
    Piper, H.
    Erb, N.
    Jenkins, D.
    Tavakoli, M.
    Deighton, C.
    Kitas, G. D.
    MUSCULOSKELETAL CARE, 2006, 4 (04) : 204 - 222